Description
ADCC-Enhanced anti-NIK (Pep 12-629-62-18) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Autoimmune Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced NIK antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
mitogen-activated protein kinase kinase kinase 14
Background
This gene encodes mitogen-activated protein kinase kinase kinase 14, which is a serine/threonine protein-kinase. This kinase binds to TRAF2 and stimulates NF-kappaB activity. It shares sequence similarity with several other MAPKK kinases. It participates in an NF-kappaB-inducing signalling cascade common to receptors of the tumour-necrosis/nerve-growth factor (TNF/NGF) family and to the interleukin-1 type-I receptor.
Alternative Names
MAP3K14; mitogen-activated protein kinase kinase kinase 14; HS; NIK; HSNIK; FTDCR1B; NF-kappa-beta-inducing kinase; serine/threonine-protein kinase NIK
Cellular Localization
Cytoplasm
Involvement in Disease
Diseases associated with MAP3K14 include Nik Deficiency and Pancreatic Ductal Adenocarcinoma.
Related Pathways
Its related pathways are CD28 co-stimulation and Bacterial infections in CF airways.
Function
Lymphotoxin-activated kinase seems to be only involved in the activation of nf-kpa-b and its transcriptional activity. Promote NFKB2/P100 proteolysis process, thereby activating nf-kpa-b through non-standard pathway. Can function in a receptor-selective manner.
Field of research
Cell Biology and Cellular Response antibody; Cell Death antibody; Signaling Transduction antibody
Post-translational modifications
Autophosphorylated. Phosphorylation at Thr-559 is required to activates its kinase activity and 'Lys-63'-linked polyubiquitination. Phosphorylated by CHUK/IKKA leading to MAP3K14 destabilization. Ubiquitinated. Undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. 'Lys-48'-linked polyubiquitination leads to its degradation by the proteasome, while 'Lys-63'-linked polyubiquitination stabilizes and activates it.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Pep 12-629-62-18
Description
This is an antibody capable of specifically binding the amino acid sequence of NF-kgr B-inducing kinase (NIK) MAP3K14, used for treatment including malignant diseases and diseases associated with pathological immune responses, such as autoimmune, allergic, inflammatory, and transplantation-related diseases.
Antibody Indication
Autoimmune Diseases
